Investing.com - Cellectis reported on Thursday second quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Cellectis announced earnings per share of $-0.36 on revenue of $2.76M. Analysts polled by Investing.com anticipated EPS of $-0.5144 on revenue of $23.46M.
Cellectis shares are down 61.58% from the beginning of the year and are trading at $3.12 , down-from-52-week-high.They are under-performing the Nasdaq which is down 18.69% from the start of the year.
Cellectis follows other major Healthcare sector earnings this month
Cellectis's report follows an earnings beat by UnitedHealth on Friday, July 15, 2022, who reported EPS of $5.57 on revenue of $80.33B, compared to forecasts EPS of $5.21 on revenue of $79.68B.
J&J had beat expectations on Tuesday, July 19, 2022 with second quarter EPS of $2.59 on revenue of $24.02B, compared to forecast for EPS of $2.54 on revenue of $23.77B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar